Click here to download the Derm Update 2005 Program in Acrobat PDF format.
Thursday, November 3, 2005 – Salle deBal Centre & Est
9:30 – 11:00
|
Case Studies in Onychomycosis
Review & discuss treatment options from case presentations. Treatments for standard as well as more complex cases will be discussed including: Relapse & recurrence, Onychomycosis in children, Hyperkeratotic & onycholytic nails, Dermatophytoma with Lunular Involvement, and The diabetic patient. Interaction with the audience on treatment approaches will be facilitated through touch pads. |
|
| 9:30 |
Introduction |
Dr. Kirk Barber |
| 9:35 |
Case presentations with Q&A after each case |
Dr. Ron Vender |
| 10:15 |
Case presentations with Q&A after each case |
Dr. Aditya Gupta |
| 10:55 |
Summary |
Dr. Kirk Barber |
| 2:00 – 3:30 |
Shaping the Management of Psoriasis – Achieving Long-Term Control with Efalizumab |
|
| 2:00 |
Chair Welcome and Introduction: Long-term Control –
An Unmet Need in Psoriasis |
Dr. Yves Poulin |
| 2:10 |
A Favourable Benefit/Risk Ratio with Efalizumab – A Targeted
T-cell Agent |
Dr. Wayne Gulliver |
| 2:30 |
Strategies for Optimizing Treatment of Efalizumab |
Dr. Kim Papp |
| 2:50 |
Not All Biologics Are the Same – Patient/Treatment Selection
Considerations |
Dr. Neil Shear |
| 3:10 |
Question and Answer |
|
| 3:25 |
Closing Comments |
Dr. Yves Poulin |
| 4:00 – 5:30 |
Taking Control over Eczema: How to Meet Patients’ Needs |
|
| 4:00 |
The Eczema Continuum |
Dr. Neal Shear |
| 4:15 |
Factors to consider when choosing a treatment |
Dr. Lawrence F. Eichenfield |
| 4:35 |
Providing long-term control |
Dr. Lawrence F. Eichenfield |
| 4:55 |
The future in the treatment of eczema |
Dr. Neal Shear |
| 5:15 |
Q & A session |
Dr. Lawrence F. Eichenfield,
Dr. Neil Shear |
|
|
|
Friday, November 4, 2005 – Salle de Bal Centre & Est
9:30 – 11:00
|
New Comparative Data in the Treatment of NMSC and Insights into the Future |
|
| 9:30 |
Welcome and Introduction |
Dr. Jason Rivers |
| 9:35 |
Tolls "R" Us |
Dr. Mark Tomai |
| 10:05 |
Clinical Advances in the Treatment of AK |
Prof. Eggert Stockfleth |
| 10:35 |
Questions and Discussion |
|
| 10:55 |
Closing Comments |
Dr. Jason Rivers |
| 11:30 – 1:30 |
Psoriatic Arthritis and Psoriasis - A 2005 Clinical Management |
|
| 11:30 |
Introduction, Learning Objectives |
Dr. Ian Landells |
| 11:35 |
Psoriatic Arthritis Clinical Update –
New Learnings from the Introduction of TNF Antagonists |
Dr. Philip Mease |
| 12:30 |
Psoriasis Clinical Update –
Interpreting the Latest Clinical Data |
Dr. Alexa Kimball |
| 13:10 |
Questions and Answers |
|
| 13:10 |
Adjourn |
|
| 2:00 – 3:30 |
AMEVIVETM: Redefining Efficacy in Psoriasis through Remission |
|
| 2:00 |
Opening |
Dr. Wayne Carey |
| 2:10 |
US experience with biologics |
Dr. Jennifer Cather |
| 2:40 |
New Data: Psoriatic Arthritis and Amevive |
Dr. M. Khraishi |
| 2:55 |
Amevive in Your Practice |
Dr. Charles Lynde |
| 3:10 |
Questions |
|
| 3:25 |
Closing |
|
| 3:30 |
Adjourn |
|
|
|
|
Saturday, November 5, 2005 – Sal de Bal Ouest
Sunday, November 6, 2005 – Salon 1, Level 2
| 8:30 - 10:55 |
The Changing Face of Dermatology Clinical Trials in Canada: Chairman - Lynne Bulger, Co-chair - Dr. Paul Kidson |
|
| 8:30 |
Welcome and Introduction |
Lynne Bulger |
| 8:35 |
Challenges in the conduct of biologic trials. |
Dr. Wayne Gulliver |
| 8:55 |
Challenges in the conduct of vaccine trials. |
Dr. Chuck Lynde |
| 9:15 |
Challenges in the conduct of Botox trials. |
Dr. Kevin Smith |
| 9:35 |
Break |
|
| 9:45 |
Inter-rater reliability in acne and atopic dermatitis trials. |
Lynne Bulger |
| 10:10 |
Factors influencing site selection. |
Dr. Paul Kidson |
| 10:35 |
The role of Health Canada in the conduct of clinical trials. |
Dr. Norman Viner,
Clinical Trial Division Chief,
HPFB, Health Canada |
| 10:55 |
Summary and close |
Dr. Stuart Maddin |
|
|
|
|
